908 Devices (MASS) Q2 2026 earnings summary

Executive summary

• Q2 2026 revenue grew 23% year-over-year to $16.1 million, driven by strong handheld device sales, new product launches, and significant momentum from U.S. state and local customers representing over half of revenues.

• Integrated NIRLab acquisition, expanding the narcotics detection portfolio with an AI-powered, subscription-based platform and strengthening market position.

• Divested bioprocessing desktop portfolio in 2025 to focus on core handheld markets, expanding installed base to over 4,100 devices globally.

• Benefiting from secular tailwinds such as increased defense budgets, opioid crisis response, and border security needs.

• Net loss from continuing operations was $11.9 million in Q2 2026, improved from the prior year.

Financial highlights

• Q2 2026 revenue: $16.1 million, up 23% year-over-year; recurring revenue was $4.9 million (31% of total), mainly from software and FTIR service.

• Gross margin was 52% (GAAP), with adjusted gross margin at 57% in Q2 2026.

• Cash, cash equivalents, and marketable securities totaled $101.5 million at quarter end, with no debt.

• Adjusted EBITDA loss was $1.9 million in Q2 2026, a 50%+ improvement year-over-year.

• Product revenue for H1 2026 was $23.7 million, up from $18.1 million in H1 2025.

Outlook and guidance

• Full-year 2026 revenue guidance raised to $68–$70 million, representing 21–25% year-over-year growth.

• Handheld product and service revenue expected to grow 23–27% year-over-year ($65–$67 million).

• Recurring revenue expected to reach up to 50% of total in 2026, with a 99% retention rate.

• Adjusted gross margins expected in the mid to high 50% range for 2026.

• Adjusted EBITDA loss projected to be in the mid-single digit millions, closing in on breakeven.